Zobrazeno 1 - 10 of 33 pro vyhledávání: '"Karien Bloem"'
2
Akademický článek
Toll-Like Receptor 4 Triggering Promotes Cytosolic Routing of DC-SIGN-Targeted Antigens for Presentation on MHC Class I
Autor: Sophie K. Horrevorts, Sanne Duinkerken, Karien Bloem, Pablo Secades, Hakan Kalay, René J. Musters, Sandra J. van Vliet, Juan J. García-Vallejo, Yvette van Kooyk
Publikováno v: Frontiers in Immunology, Vol 9 (2018)
DC-SIGN is an antigen uptake receptor expressed on dendritic cells (DCs) with specificity for glycans present on a broad variety of pathogens and is capable of directing its cargo to MHC-I and MHC-II pathways for the induction of CD8+ and CD4+ T cell
Externí odkaz: https://doaj.org/article/a8955d655ab94cdfa3526738c7c4aeb2
Zobrazit plný text záznamu
3
Akademický článek
Ligand binding and signaling of dendritic cell immunoreceptor (DCIR) is modulated by the glycosylation of the carbohydrate recognition domain.
Autor: Karien Bloem, Ilona M Vuist, Arend-Jan van der Plas, Léon M J Knippels, Johan Garssen, Juan J García-Vallejo, Sandra J van Vliet, Yvette van Kooyk
Publikováno v: PLoS ONE, Vol 8, Iss 6, p e66266 (2013)
C-type lectins are innate receptors expressed on antigen-presenting cells that are involved in the recognition of glycosylated pathogens and self-glycoproteins. Upon ligand binding, internalization and/or signaling often occur. Little is known on the
Externí odkaz: https://doaj.org/article/1f3d3cb9dc4047b786111aeb07589368
Zobrazit plný text záznamu
4
Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis
Autor: Alyssa A Toorop, Laura Hogenboom, Karien Bloem, Merve Kocyigit, Nadine W M Commandeur, Anne Wijnants, Birgit I Lissenberg-Witte, Eva M M Strijbis, Bernard M J Uitdehaag, Theo Rispens, Joep Killestein, Zoé L E van Kempen
Publikováno v: Journal of Neurology, Neurosurgery and Psychiatry, 94(6):jnnp-2022-330793, 487-493. BMJ Publishing Group
Toorop, A A, Hogenboom, L, Bloem, K, Kocyigit, M, Commandeur, N W M, Wijnants, A, Lissenberg-Witte, B I, Strijbis, E M M, Uitdehaag, B M J, Rispens, T, Killestein, J & van Kempen, Z L E 2023, ' Ocrelizumab concentration and antidrug antibodies are associated with B-cell count in multiple sclerosis ', Journal of Neurology, Neurosurgery and Psychiatry, vol. 94, no. 6, jnnp-2022-330793, pp. 487-493 . https://doi.org/10.1136/jnnp-2022-330793
Journal of Neurology, Neurosurgery and Psychiatry. BMJ Publishing Group
BackgroundThe majority of patients with multiple sclerosis on ocrelizumab have B-cell depletion after standard interval dosing of 26 weeks. With B-cell-guided dosing patients receive their next dose when B-cell repopulation occurs. Prediction of B-ce
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05bf53014caba07c88a1fad212b74485
https://research.vumc.nl/en/publications/300cca69-bb4f-4bfb-9887-1f40967fbd8f
Zobrazit plný text záznamu
5
Drug-tolerant detection of anti-drug antibodies in an antigen-binding assay using europium chelate fluorescence
Autor: Jolinde van Strien, Lisanne Dijk, Sadaf Atiqi, Rogier Schouten, Karien Bloem, Gerrit Jan Wolbink, Floris Loeff, Theo Rispens
Publikováno v: Journal of Immunological Methods, 514:113436. Elsevier
van Strien, J, Dijk, L, Atiqi, S, Schouten, R, Bloem, K, Wolbink, G J, Loeff, F & Rispens, T 2023, ' Drug-tolerant detection of anti-drug antibodies in an antigen-binding assay using europium chelate fluorescence ', Journal of Immunological Methods, vol. 514, 113436 . https://doi.org/10.1016/j.jim.2023.113436
Journal of immunological methods, 514:113436. Elsevier
Accurate anti-drug antibody (ADA) measurements in patient sera requires dissociation of ADA-drug complexes combined with sensitive and specific ADA detection. Bridging type immunoassays are often used despite several disadvantages associated with thi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0accf1fa798ec593b606aff9e4ea7f99
https://research.vumc.nl/en/publications/e99f1637-94bf-4cda-a0a9-662c6ae571c8
Zobrazit plný text záznamu
6
Drug levels, anti-drug antibodies and B-cell counts were not predictive of response in rheumatoid arthritis patients on (ultra-)low-dose rituximab
Autor: Maike H M Wientjes, Titia M G Gijzen, Nathan den Broeder, Karien Bloem, Annick de Vries, Bart J F van den Bemt, Alfons A den Broeder, Lise M Verhoef
Publikováno v: Rheumatology, 61, 10, pp. 3974-3980
Rheumatology, 61, 3974-3980
Objectives The REDO trial (REtreatment with Rituximab in RhEumatoid arthritis: Disease Outcome after Dose Optimisation) showed that ultra-low-dose rituximab (500 mg or 200 mg) was similarly effective to a 1000 mg dosage in the majority of RA patients
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41cd1c027d1b60a6785339e1ab4337aa
https://hdl.handle.net/2066/283275
Zobrazit plný text záznamu
10
Infliximab Level Between Venous and Capillary Blood Using Novel Device Strongly Correlate in Paediatric Inflammatory Bowel Disease Patients
Autor: Karien Bloem, Maria M E Jongsma, Annick de Vries, Tiny Schaap, Marieke Zijlstra, Lissy de Ridder
Publikováno v: Journal of Pediatric Gastroenterology and Nutrition, 72(1), 56-60. Lippincott Williams & Wilkins
Objectives: Blood to measure infliximab (IFX) levels is typically obtained with venipuncture. Dried blood sampling (DBS), using capillary blood obtained from a finger prick, would be an alternative to measure IFX blood levels while being more patient
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40b844e0996a47f519ec8a2769e47b28
https://pubmed.ncbi.nlm.nih.gov/32804907
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje